Budgetary impact analysis of qPCR P210 test incorporation for the follow-up for patients with chronic myeloid leukemia in a tertiary hospital in the Federal District, Brazil

Authors

  • Camila Yumi Ushirobira Instituto de Gestão Estratégica de Saúde do Distrito Federal, SRTV 702, Via W5 Norte - Brasília - DF CEP: 70.335-900
  • Vanessa Nascimento de Andrade Bastos Instituto de Gestão Estratégica de Saúde do Distrito Federal, SRTV 702, Via W5 Norte - Brasília - DF CEP: 70.335-900
  • Larissa Ferreira da Silva Instituto de Gestão Estratégica de Saúde do Distrito Federal, Diretoria de Ensino e Pesquisa (DIEP) Setor Médico Hospitalar Sul QD 301 Edifício CPD - Asa Sul, Brasília - DF, CEP 70335-902, Brasil.
  • Jessica Amarante de Oliveira Instituto de Gestão Estratégica de Saúde do Distrito Federal, Instituto de Gestão Estratégica de Saúde do Distrito Federal, SRTV 702, Via W5 Norte - Brasília - DF CEP: 70.335-900

DOI:

https://doi.org/10.14450/2318-9312.v35.e2.a2023.pp214-222

Keywords:

leukemia, myeloid, chronic-phase, protein kinase inhibitors, polymerase chain reaction, guidelines, costs and cost analysis

Abstract

Chronic Myeloid Leukemia (CML) is a disease that affects people aged between 40 and 60 years, mainly males. In most cases, expression of the Philadelphia chromosome occurs, which induces the production of an oncoprotein with increased tyrosine kinase activity, expected in unbridled anticipation of cells. The treatment of first choice is currently the tyrosine kinase inhibitor, Imatinib, which leads to a decrease in the number of cases of evolution from the chronic to the accelerated phase and for the proper monitoring of the molecular response of the disease, it is necessary to carry out screening tests such as qPCR, the gold standard of detection. In this work, a study was carried out to analyze the budgetary impact of incorporating the qPCR test by a tertiary hospital in the Federal District to improve CML screening to promote continuity in patient care. A budget impact analysis (BIA) was performed to evaluate the incorporation of the qPCR BCR-ABL p210 test for monitoring chronic myeloid leukemia in patients in the Federal District, compared to carrying out the tests through a contract with a third-party laboratory. According to the AIO, the contract had a smaller budgetary impact than the incorporation of qPCR test by the hospital. For instance, it is better to keep the current contract.

Author Biographies

Camila Yumi Ushirobira, Instituto de Gestão Estratégica de Saúde do Distrito Federal, SRTV 702, Via W5 Norte - Brasília - DF CEP: 70.335-900

Farmacêutica clínica e Industrial (2017) e mestre em ciências farmacêuticas pela UnB (2019). Residência em oncologia pelo IGESDF (2023).

Vanessa Nascimento de Andrade Bastos, Instituto de Gestão Estratégica de Saúde do Distrito Federal, SRTV 702, Via W5 Norte - Brasília - DF CEP: 70.335-900

Farmacêutica clínica e hospitalar. Residência em oncologia pelo IGESDF (2023).

Larissa Ferreira da Silva, Instituto de Gestão Estratégica de Saúde do Distrito Federal, Diretoria de Ensino e Pesquisa (DIEP) Setor Médico Hospitalar Sul QD 301 Edifício CPD - Asa Sul, Brasília - DF, CEP 70335-902, Brasil.

Farmacêutica pela SES-DF e IGESDF na área de ATS (avaliação de tecnologias em saúde). Residência em UTI pela SES-DF.

Jessica Amarante de Oliveira, Instituto de Gestão Estratégica de Saúde do Distrito Federal, Instituto de Gestão Estratégica de Saúde do Distrito Federal, SRTV 702, Via W5 Norte - Brasília - DF CEP: 70.335-900

Nutricionista pelo Centro Universitário São Camilo (2013) e mestrado em Mestrado acadêmico em Ciências da Saúde pela Escola Superior de Ciências da Saúde (2019). Atualmente é coordenadora residência multiprofissional - Instituto de Gestão Estratégica de Saúde do Distrito Federal IGESDF e nutricionista - Instituto de Gestão Estratégica de Saúde do Distrito Federal IGESDF.

Downloads

Published

2023-07-03

How to Cite

Ushirobira, C. Y., Bastos, V. N. de A., da Silva, L. F., & de Oliveira, J. A. (2023). Budgetary impact analysis of qPCR P210 test incorporation for the follow-up for patients with chronic myeloid leukemia in a tertiary hospital in the Federal District, Brazil. Infarma - Pharmaceutical Sciences, 35(2), 214–222. https://doi.org/10.14450/2318-9312.v35.e2.a2023.pp214-222

Issue

Vol. 35 No. 2 (2023)

Section

Original article

License

Authors who publish in this journal agree to the following terms:

 

  1. Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
  2. Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
  3. Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).